the firm's post-grant practitioners are some of the most experienced in the country.

Technologies

Artificial Intelligence (AI)
Artificial Intelligence (AI)
Digital Health
Digital Health
Energy & Renewables
Energy & Renewables

Fast Facts

About Our

Law Firm

About Our Law Firm

Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.

Get to know our

History

Get to know our History

1968
Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.

Our Local and

Global Reach

Our Local and Global Reach

Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.

A few of our

ACCOLADES

A few of our ACCOLADES

Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.

OPPORTUNITIES FOR YOUR

Career

OPPORTUNITIES FOR YOUR Career

From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.

A few ways to

GET In Touch

A few ways to GET In Touch
US Office

Telephone: 703-413-3000
Learn More +


Tokyo Office

Telephone: +81-3-6212-0550
Learn More +

Downloadable

Patent Forms

Downloadable Patent Forms

The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.

Stay informed with

Our Blogs

FDA To Host Public Hearing Regarding Approved Pathway for Biologics

  • October 13, 2010
  • Blog Post

The FDA will host a 2 day public hearing on November 2-3, 2010 between 8:30 am and 4:30 pm regarding the approval pathway for biological products that are highly similar (biosimilar) to or interchangeable with an FDA-licensed biological product. The hearing will seek input from the public regarding the implementation of theBiologics Price Competition and Innovation Act of 2009. The Federal Register Notice detailing the topics for the hearing can be found in the above pdf link "FR Notice". The hearing will take place at the FDA White Oak Campus, 10903 New Hampshire Avenue, Bldg. 31, Room 1503, Silver Spring, Maryland 20993.

The hearing will also be webcast for those unable to attend. The webcast can be accessed via the following links:

November 2, 2010: https://collaboration.fda.gov/part15day1/
November 3, 2010: https://collaboration.fda.gov/part15day2/

Resources